VIVUS Inc (NASDAQ:VVUS) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 36,397,351 shares, an increase of 4.1% from the April 15th total of 34,947,571 shares, AR Network reports. Based on an average trading volume of 2,454,420 shares, the days-to-cover ratio is currently 14.8 days. Currently, 36.3% of the shares of the stock are sold short. VIVUS, Inc. (NASDAQ:VVUS) weekly performance is -7.65%. On last trading day company shares ended up $4.83. Analysts mean target price for the company is $7.33. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is -11.90%.
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) says it has not been contacted or investigated by Chinese authorities over allegations of corruption, while a Novartis spokeswoman says she is not aware of any contact from authorities around corruption. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) shares advanced 0.86% in last trading session and ended the day on $37.72 .
Shares of Arena Pharmaceuticals Inc (NASDAQ:ARNA) were the recipient of a large drop in short interest during the month of April. As of April 30th, there was short interest totalling 50,611,732 shares, a drop of 4.3% from the April 15th total of 52,859,238 shares, Analyst Ratings News reports. Currently, 23.3% of the company’s shares are short sold. Based on an average trading volume of 4,298,044 shares, the short-interest ratio is presently 11.8 days. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved up 0.94% in last trading session and was closed at $6.43, while trading in range of $6.29 – $6.55. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is 9.91%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the first quarter of 2014, including revenue from sales of Iclusig (ponatinib) and licensing agreements. The Company also provided an update on corporate developments. Total revenue for the quarter ended March 31, 2014 was $11.8 million, which includes product revenue from sales of Iclusig and license revenue. Net loss for the quarter ended March 31, 2014 was $49.8 million, or $0.27 per share, compared to net loss of $64.7 million, or $0.36 per share, for the same period in 2013. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended the last trading day at $6.36. Company weekly volatility is calculated as 4.44% and price to cash ratio as 5.01. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a negative weekly performance of -4.65%.
MannKind Corporation (NASDAQ:MNKD) has developed a product called AFREZZA for the delivery of insulin in Type 1 and Type 2 diabetic patients. The simplistic description of AFREZZA is that it’s an insulin inhaler that could render insulin injections obsolete in the future. MNKD presented its clinical trials data to an FDA Advisory Panel in April and that panel overwhelmingly recommended AFREZZA for FDA approval. The FDA calendar currently has AFREZZA scheduled for review on July 15th. MannKind and its investors have a lot at stake pending the FDA approval in July. MannKind Corporation (NASDAQ:MNKD) weekly performance is 12.86%. On last trading day company shares ended up $7.02. Analysts mean target price for the company is $8.07. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 15.26%.
Leave a Reply